George C Prendergast

List of Publications by Year
in descending order

157 papers	12,870 citations	24978 57 h-index	23472 111 g-index
165 all docs	165 docs citations	165 times ranked	14740 citing authors

#	Article	IF	Citations
1	The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism. Journal of Immunology, 2022, 208, 571-581.	0.4	13
2	IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNÎ³/IL6 Balance to Promote Neovascularization. Cancer Immunology Research, 2021, 9, 514-528.	1.6	16
3	The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Molecular Cancer Therapeutics, 2021, 20, 2166-2176.	1.9	19
4	Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 789473.	2.2	2
5	Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. Frontiers in Immunology, 2020, 11, 1861.	2.2	70
6	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research, 2020, 26, 5232-5245.	3.2	52
7	Abstract 1474: IDO1 signaling supports inflammatory neovascularization. , 2020, , .		0
8	Immune control by amino acid catabolism during tumorigenesis andÂtherapy. Nature Reviews Cancer, 2019, 19, 162-175.	12.8	170
9	Bin1 antibody lowers the expression of phosphorylated Tau in Alzheimer's disease. Journal of Cellular Biochemistry, 2019, 120, 18320-18331.	1.2	7
10	Capture and display of antibodies secreted by hybridoma cells enables fluorescent on-cell screening. MAbs, 2019, 11, 546-558.	2.6	11
11	Preclinical study of the longâ€range safety and antiâ€inflammatory effects of highâ€dose oral meglumine. Journal of Cellular Biochemistry, 2019, 120, 12051-12062.	1.2	5
12	Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissues. Methods in Enzymology, 2019, 629, 219-233.	0.4	2
13	Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Seminars in Immunopathology, 2019, 41, 41-48.	2.8	198
14	Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. European Journal of Medicinal Chemistry, 2019, 162, 455-464.	2.6	37
15	RhoB antibody alters retinal vascularization in models of murine retinopathy. Journal of Cellular Biochemistry, 2019, 120, 9381-9391.	1.2	4
16	Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers. Clinical Cancer Research, 2019, 25, 724-734.	3.2	48
17	Intestinal barrier tightening by a cellâ€penetrating antibody to Bin1, a candidate target for immunotherapy of ulcerative colitis. Journal of Cellular Biochemistry, 2019, 120, 4225-4237.	1.2	16
18	Abstract A101: IDO2 host genetic status influences progression and radiotherapy response in pancreatic ductal adenocarcinoma. , 2019, , .		0

#	Article	IF	Citations
19	A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. Journal of the American College of Surgeons, 2018, 226, 596-603.	0.2	5
20	CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. Cancer Research, 2018, 78, 1657-1671.	0.4	97
21	Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive â€˜Coldâ€™ Tumors â€˜Hotâ€™. Trends in Cancer, 2018, 4, 38-58.	3.8	130
22	IDO/TDO Inhibition in Cancer. , 2018, , 289-307.		1
23	Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. International Review of Cell and Molecular Biology, 2018, 336, 175-203.	1.6	204
24	Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Frontiers in Oncology, 2018, 8, 370.	1.3	91
25	Tu1742 - BIN1 Mab as a Novel Immunotherapy for the Treatment of Ulcerative Colitis. Gastroenterology, 2018, 154, S-1007.	0.6	0
26	Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis. Clinical Immunology, 2017, 179, 8-16.	1.4	44
27	The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. Cancer Research, 2017, 77, 1783-1812.	0.4	270
28	RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus. DMM Disease Models and Mechanisms, 2017, 10, 1313-1322.	1.2	7
29	Discovery of IDO1 Inhibitors: From Bench to Bedside. Cancer Research, 2017, 77, 6795-6811.	0.4	433
30	Investigation of the Tissue Distribution and Physiological Roles of Indoleamine 2,3-Dioxygenase-2. International Journal of Tryptophan Research, 2017, 10, 117864691773509.	1.0	33
31	Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nausea. Supportive Care in Cancer, 2017, 25, 581-587.	1.0	0
32	Bin1. , 2017, , 500-501.		0
33	Abstract 2680: A novel pro-tumorigenic role for IDO1 in inflammatory neovascularization. , 2017, , .		0
34	Cancer Research: 75th Anniversary of the Field's Most Highly Cited Basic Science Journal. Cancer Research, 2016, 76, 3-3.	0.4	9
35	A Milestone Review on How Macrophages Affect Tumor Growth. Cancer Research, 2016, 76, 6439-6442.	0.4	75
36	IDO1 is an Integral Mediator of Inflammatory Neovascularization. EBioMedicine, 2016, 14, 74-82.	2.7	75

#	Article	IF	Citations
37	IDO2 Modulates T Cellâ€“Dependent Autoimmune Responses through a B Cellâ€“Intrinsic Mechanism. Journal of Immunology, 2016, 196, 4487-4497.	0.4	56
38	Cancer Vaccines: A Brief Overview. Methods in Molecular Biology, 2016, 1403, 755-761.	0.4	104
39	BIN1 regulates BACE1 intracellular trafficking and amyloid-Î² production. Human Molecular Genetics, 2016, 25, ddw146.	1.4	67
40	Neuroprotective effect of Myo/Nog cells in the stressed retina. Experimental Eye Research, 2016, 146, 22-25.	1.2	15
41	How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. Oncologist, 2016, 21, 233-243.	1.9	71
42	O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. European Journal of Medicinal Chemistry, 2016, 108, 564-576.	2.6	33
43	Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. Digestive Diseases and Sciences, 2016, 61, 423-432.	1.1	14
44	Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer. Oncotarget, 2016, 7, 7372-7380.	0.8	3
45	Abstract PR09: c-MYC preserves genomic integrity during DNA replication: a paradigm shift of c-MYC. , 2016, , .		0
46	Cardiacâ€Specific Disruption of Bin1 in Mice Enables a Model of Stressâ€•and Ageâ€Associated Dilated Cardiomyopathy. Journal of Cellular Biochemistry, 2015, 116, 2541-2551.	1.2	27
47	A Perspective on Cancer as an Abortive Autoimmune Response to Altered-Self. Cancer Research, 2015, 75, 3-4.	0.4	19
48	Abstract P6-08-54: TIMP-4 is a prognostic and predictive marker in triple-negative breast cancers. , 2015, , .		1
49	Abstract 5223: A novel pro-angiogenic role for IDO1 in inflammatory tumor promotion. , 2015, , .		0
50	Meglumine Exerts Protective Effects against Features of Metabolic Syndrome and Type II Diabetes. PLoS ONE, 2014, 9, e90031.	1.1	6
51	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
52	1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity, 2014, 47, 409-418.	1.2	18
53	IDO2 in Immunomodulation and Autoimmune Disease. Frontiers in Immunology, 2014, 5, 585.	2.2	112
54	IDO2 Is a Critical Mediator of Autoantibody Production and Inflammatory Pathogenesis in a Mouse Model of Autoimmune Arthritis. Journal of Immunology, 2014, 192, 2082-2090.	0.4	104

#	Article	IF	Citations
55	IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. International Immunology, 2014, 26, 357-367.	1.8	168
56	IDO in Inflammatory Programming and Immune Suppression in Cancer. , 2014, , 311-346.		2
57	Editors' Viewpointâ€"Response. Cancer Research, 2014, 74, 635-635.	0.4	0
58	Specific In Situ Detection of Murine Indoleamine 2, 3â€‹scp›D‹/scp›ioxygenase. Journal of Cellular Biochemistry, 2014, 115, 391-396.	1.2	8
59	The SOCS3-Independent Expression of IDO2 Supports the Homeostatic Generation of T Regulatory Cells by Human Dendritic Cells. Journal of Immunology, 2014, 192, 1231-1240.	0.4	72
60	Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunology, Immunotherapy, 2014, 63, 721-735.	2.0	423
61	Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature, 2014, 511, 184-190.	13.7	574
62	Abstract 3665: IDO1 is an integrative determinant of tumor-promoting, pathogenic inflammation. , 2014, , .		1
63	The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis. Developmental Biology, 2013, 382, 160-171.	0.9	28
64	Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial. Journal of Radiation Oncology, 2013, 2, 315-321.	0.7	52
65	IDO in Immune Escape. , 2013, , 565-581.		1
66	A bioactive probe of the oxidative pentose phosphate cycle: Novel strategy to reverse radioresistance in glucose deprived human colon cancer cells. Toxicology in Vitro, 2013, 27, 367-377.	1.1	5
67	AACR Cancer Progress Report 2013. Clinical Cancer Research, 2013, 19, S1-S98.	3.2	55
68	RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nature Communications, 2013, 4, 2824.	5.8	51
69	RhoB Differentially Controls Akt Function in Tumor Cells and Stromal Endothelial Cells during Breast Tumorigenesis. Cancer Research, 2013, 73, 50-61.	0.4	38
70	Abstract B070: TIMP-4 â€" prognostic marker and treatment target for triple-negative breast cancers. , 2013, , .		0
71	Opposing Biological Functions of Tryptophan Catabolizing Enzymes During Intracellular Infection. Journal of Infectious Diseases, 2012, 205, 152-161.	1.9	121
72	A perspective on new immune adjuvant principles. OncoImmunology, 2012, 1, 924-929.	2.1	14

#	Article	IF	Citations
73	Role of RhoB in the Regulation of Pulmonary Endothelial and Smooth Muscle Cell Responses to Hypoxia. Circulation Research, 2012, 110, 1423-1434.	2.0	77
74	IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. OncoImmunology, 2012, 1, 1460-1468.	2.1	338
75	Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future. OncoImmunology, 2012, 1, 793-797.	2.1	14
76	Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunological Reviews, 2012, 249, 135-157.	2.8	165
77	IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development. Cancer Discovery, 2012, 2, 722-735.	7.7	280
78	Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro. Toxicology in Vitro, 2012, 26, 603-612.	1.1	21
79	Bin1 Attenuation Suppresses Experimental Colitis by Enforcing Intestinal Barrier Function. Digestive Diseases and Sciences, 2012, 57, 1813-1821.	1.1	15
80	RIN3 Is a Negative Regulator of Mast Cell Responses to SCF. PLoS ONE, 2012, 7, e49615.	1.1	42
81	Abstract 295: IDO drives tumor-promoting, pathogenic inflammation in lung. , 2012, , .		0
82	Human Blood Dendritic Cells Induce Tregs Through the PGE2-Independent Expression of an Active Form of IDO2 Enzyme. Blood, 2012, 120, 1047-1047.	0.6	0
83	Lactoferrinâ€“Endothelin-1 Axis Contributes to the Development and Invasiveness of Triple-Negative Breast Cancer Phenotypes. Cancer Research, 2011, 71, 7259-7269.	0.4	36
84	Indoleamine 2,3-Dioxygenase Amino Acid Metabolism and Tumour-Associated Macrophages: Regulation in Cancer-Associated Inflammation and Immune Escape. , 2011, , 91-104.		0
85	RhoB Loss Prevents Streptozotocin-Induced Diabetes and Ameliorates Diabetic Complications in Mice. American Journal of Pathology, 2011, 178, 245-252.	1.9	14
86	Why tumours eat tryptophan. Nature, 2011, 478, 192-194.	13.7	130
87	Altered apoptotic responses in neurons lacking RhoB GTPase. European Journal of Neuroscience, 2011, 34, 1737-1746.	1.2	15
88	RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. Journal of Cellular Biochemistry, 2011, 112, 1572-1584.	1.2	34
89	Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biology and Therapy, 2011, 12, 1050-1058.	1.5	45
90	PGE2-Independent Expression of Indoleamine 2,3-Dioxygenase-2 (IDO2) Supports the Tolerogenic Function of Monocyte-Derived Dendritic Cells,. Blood, 2011, 118, 3231-3231.	0.6	0

#	Article	IF	Citations
91	Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunology, Immunotherapy, 2010, 59, 1655-1663.	2.0	57
92	Induction of IDO-1 by Immunostimulatory DNA Limits Severity of Experimental Colitis. Journal of Immunology, 2010, 184, 3907-3916.	0.4	100
93	Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy, 2010, 2, 293-297.	1.0	28
94	Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate. Cancer Research, 2010, 70, 1845-1853.	0.4	65
95	Towards a Genetic Definition of Cancer-Associated Inflammation. American Journal of Pathology, 2010, 176, 2082-2087.	1.9	71
96	Human Monocyte-Derived Dendritic Cells Are Tolerogenic through Both IDO1 and IDO2. Blood, 2010, 116, 4298-4298.	0.6	0
97	The Immunoregulatory Enzyme IDO Paradoxically Drives B Cell-Mediated Autoimmunity. Journal of Immunology, 2009, 182, 7509-7517.	0.4	111
98	IDO recruits Tregs in melanoma. Cell Cycle, 2009, 8, 1818-1822.	1.3	27
99	BAR the door: Cancer suppression by amphiphysin-like genes. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1795, 25-36.	3.3	47
100	Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target. Journal of the American College of Surgeons, 2009, 208, 781-787.	0.2	118
101	Indoleamine 2,3â€dioxygenase in Tâ€cell tolerance and tumoral immune escape. Immunological Reviews, 2008, 222, 206-221.	2.8	368
102	Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase. Journal of Medicinal Chemistry, 2008, 51, 4968-4977.	2.9	148
103	Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 1706-1718.	2.9	151
104	Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17073-17078.	3.3	214
105	Bin3 Deletion Causes Cataracts and Increased Susceptibility to Lymphoma during Aging. Cancer Research, 2008, 68, 1683-1690.	0.4	27
106	Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biology and Therapy, 2007, 6, 192-194.	1.5	25
107	Cancer Immunologists and Cancer Biologists: Why We Didn't Talk Then but Need to Now. Cancer Research, 2007, 67, 3500-3504.	0.4	90
108	Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer. Current Cancer Drug Targets, 2007, 7, 31-40.	0.8	125

#	Article	IF	Citations
109	Bin1 Interacts with and Restrains the DNA End-Binding Protein Complex Ku. Cell Cycle, 2007, 6, 1914-1918.	1.3	15
110	Bin1 Homolog Hob1 Supports a Rad6-Set1 Pathway of Transcriptional Repression in Fission Yeast. Cell Cycle, 2007, 6, 1655-1662.	1.3	9
111	Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses. Cancer Research, 2007, 67, 792-801.	0.4	557
112	Bin1 Ablation in Mammary Gland Delays Tissue Remodeling and Drives Cancer Progression. Cancer Research, 2007, 67, 100-107.	0.4	35
113	Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound <scp>d</scp>-1-Methyl-Tryptophan. Cancer Research, 2007, 67, 7082-7087.	0.4	453
114	RhoB Regulates PDGFR-Î² Trafficking and Signaling in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2597-2605.	1.1	60
115	Bin1 Ablation Increases Susceptibility to Cancer during Aging, Particularly Lung Cancer. Cancer Research, 2007, 67, 7605-7612.	0.4	59
116	Structureâ^'Activity Study of Brassinin Derivatives as Indoleamine 2,3-Dioxygenase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 684-692.	2.9	161
117	The Crystal Structure of the BAR Domain from Human Bin1/Amphiphysin II and Its Implications for Molecular Recognitionâ€. Biochemistry, 2006, 45, 12917-12928.	1.2	72
118	Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine, 2005, 11, 312-319.	15.2	998
119	Marrying Immunotherapy with Chemotherapy: Why Say IDO?: Figure 1.. Cancer Research, 2005, 65, 8065-8068.	0.4	105
120	Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opinion on Therapeutic Targets, 2005, 9, 831-849.	1.5	100
121	Chasing cancer: From genes to drugs. Cancer Biology and Therapy, 2005, 4, 901-905.	1.5	0
122	Pharmacokinetic and Toxicology Issues in Cancer Drug Discovery and Development. , 2004, , 255-286.		0
123	Protein Transduction Strategies for Target and Mechanism Validation. , 2004, , 91-118.		1
124	Molecular Cancer Therapeutics: Will the Promise be Fulfilled?. , 2004, , 7-40.		3
125	Applications and Issues for Tissue Arrays in Target and Drug Discovery. , 2004, , 73-90.		4
126	Intellectual Property and Commercialization Issues in Drug Discovery. , 2004, , 307-327.		0

#	Article	IF	Citations
127	Pharmacodynamic Assays in Cancer Drug Discovery: From Preclinical Validation to Clinical Trial Monitoring. , 2004, , 227-254.		0
128	Transgenic Versus Xenograft Mouse Models of Cancer: Utility and Issues. , 2004, , 203-226.		1
129	Clinical Development Issues. , 2004, , 287-306.		1
130	Cancer Genetics and Drug Target Selection. , 2004, , 41-53.		0
131	Gene Microarray Technologies for Cancer Drug Discovery and Development. , 2004, , 141-186.		0
132	Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biology and Therapy, 2004, 3, 1236-1242.	1.5	23
133	Transgenic Mouse Models of Cancer. , 2004, , 187-202.		0
134	Drug Screening: Assay Development Issues. , 2004, , 119-140.		5
135	RNA Interference in Mammals: Journey to the Center of Human Disease. , 2004, , 55-72.		0
136	Signal transduction. Cancer Cell, 2003, 4, 244-245.	7.7	19
137	Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: Diverse sites of nuclear expression and losses in prostate cancer. Journal of Cellular Biochemistry, 2003, 88, 635-642.	1.2	42
138	hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress. Oncogene, 2003, 22, 637-648.	2.6	29
139	Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene, 2003, 22, 3578-3588.	2.6	21
140	Targeted Disruption of the Murine Bin1/Amphiphysin II Gene Does Not Disable Endocytosis but Results in Embryonic Cardiomyopathy with Aberrant Myofibril Formation. Molecular and Cellular Biology, 2003, 23, 4295-4306.	1.1	118
141	RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes and Development, 2003, 17, 2721-2732.	2.7	155
142	Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clinical Cancer Research, 2003, 9, 3345-55.	3.2	46
143	Farnesyltransferase inhibitors: Potential therapeutic for inflammatory breast cancer?. Breast Disease, 2002, 15, 25-32.	0.4	3
144	Actin' up: RhoB in cancer and apoptosis. Nature Reviews Cancer, 2001, 1, 162-168.	12.8	193

#	Article	IF	Citations
145	Human BIN3 Complements the F-actin Localization Defects Caused by Loss of Hob3p, the Fission Yeast Homolog of Rvs161p. Journal of Biological Chemistry, 2001, 276, 21670-21677.	1.6	23
146	RhoB Is Dispensable for Mouse Development, but It Modifies Susceptibility to Tumor Formation as Well as Cell Adhesion and Growth Factor Signaling in Transformed Cells. Molecular and Cellular Biology, 2001, 21, 6906-6912.	1.1	203
147	Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. International Journal of Cancer, 2000, 85, 376-383.	2.3	81
148	Loss of heterozygosity and tumor suppressor activity ofBin1 in prostate carcinoma. , 2000, 86, 155-161.		84
149	The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program. Oncogene, 2000, 19, 4669-4684.	2.6	104
150	Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Current Opinion in Cell Biology, 2000, 12, 166-173.	2.6	133
151	Bin2, a Functionally Nonredundant Member of the BAR Adaptor Gene Family. Genomics, 2000, 67, 210-220.	1.3	35
152	Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene, 1999, 18, 3564-3573.	2.6	109
153	Mechanisms of apoptosis by c-Myc. Oncogene, 1999, 18, 2967-2987.	2.6	404
154	The MurineBin1Gene Functions Early in Myogenesis and Defines a New Region of Synteny between Mouse Chromosome 18 and Human Chromosome 2. Genomics, 1999, 56, 51-58.	1.3	28
155	A Role for the Putative Tumor Suppressor Bin1 in Muscle Cell Differentiation. Molecular and Cellular Biology, 1998, 18, 566-575.	1.1	100
156	Structural Analysis of the Human BIN1 Gene. Journal of Biological Chemistry, 1997, 272, 31453-31458.	1.6	124
157	BIN1 is a novel MYCâ€“interacting protein with features of a tumour suppressor. Nature Genetics, 1996, 14, 69-77.	9.4	345